Linagliptin Mitigates DMH‐Induced Colorectal Cancer in Rats: Crosstalk Between NFAT and IL‐6/JAK2/STAT3/NF‐κB Signaling Hubs
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Mohamed O Mahmoud und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt. Hauptthemen laut MEDLINE: NF-kappa B, STAT3 Transcription Factor, Interleukin-6, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a multicomponent disease and the second most frequent root of cancer‐related deaths globally. Linagliptin is a dipeptidyl peptidase‐4 (DPP‐4) inhibitor. It has been repurposed in recent experimental studies due to its marked anti‐inflammatory activities. This study aimed to evaluate the ameliorative role of linagliptin in 1,2‐dimethylhydrazine (DMH)‐induced CRC via modulation of NFAT‐mediated IL‐6 and JAK2/STAT3/NF‐κB signaling pathways. CRC model has been successfully established via a dose equal 40 mg/kg two times a week of DMH for 8‐week duration. Twenty‐four Wistar rats were segregated into three groups of eight rats each; normal control, DMH‐induced CRC and DMH + linagliptin (10 mg/kg; p.o). Linagliptin attenuated DMH‐induced oxidative stress by restoring the declined levels of some antioxidant enzymes. Linagliptin suppressed the elevated nuclear factor kappa B (NF‐κB) induced by DMH which is highlighted using immunohistochemistry analysis. The anti‐inflammatory role of linagliptin has been fortified by the decline in nuclear factor of activated T‐cells (NFAT) mRNA expression level along with the reduction in vascular endothelial growth factor (VEGF), interlukin‐6 (IL‐6) and cyclooxygenase‐2 (COX‐2) levels. Linagliptin mitigate the protein expression of DMH‐activated oncogenic janus‐activated kinase/signal transducers and activators of transcription (JAK2/STAT3). Linagliptin exerted a proapoptotic effect to tumor cells manifested by a remarkable decline in B‐cell lymphoma 2 (Bcl‐2) and a significant elevation in Bcl‐2‐associated X protein (Bax) expression levels. The histopathological analysis revealed that linagliptin has inhibitory potential against the DMH induced dysplastic aberrant crypt foci (ACF) and adenocarcinoma. Linagliptin ameliorated CRC by modulating NFAT‐mediated IL‐6 with JAK2/STAT3/NF‐κB signaling cascades.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
- Biochemistry Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.
Zitieren
APA
Mahmoud, M. O., Al-Hamid, H. A., Hassan, N. F., El-Ansary, M. R., & Gomaa, S. B. (2025). Linagliptin Mitigates DMH‐Induced Colorectal Cancer in Rats: Crosstalk Between NFAT and IL‐6/JAK2/STAT3/NF‐κB Signaling Hubs. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70206
Vancouver
Mahmoud MO, Al-Hamid HA, Hassan NF, El-Ansary MR, Gomaa SB. Linagliptin Mitigates DMH‐Induced Colorectal Cancer in Rats: Crosstalk Between NFAT and IL‐6/JAK2/STAT3/NF‐κB Signaling Hubs. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70206
BibTeX
@article{Mahmoud2025,
author = {Mahmoud, Mohamed O and Al-Hamid, Hager Abd and Hassan, Noha F and El-Ansary, Mona R and Gomaa, Safaa B},
title = {Linagliptin Mitigates DMH‐Induced Colorectal Cancer in Rats: Crosstalk Between NFAT and IL‐6/JAK2/STAT3/NF‐κB Signaling Hubs},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70206}
}
EUVIMED